RNV · ASX

Renerve Limited (ASX:RNV)

AU$0.1

 0.0025 (2.5%)
ASX:Live
30/04/2025 02:06:44 PM
Near Support Near 52 Week Low HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RNV Overview

RNV Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

RNV Price Chart

Key Stats

Market Cap

n/a

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.1 - 0.22

Trade Value (12mth)

AU$4,532.00

1 week

-9.09%

1 month

-31.03%

YTD

-41.18%

1 year

0%

All time high

0.22

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

N/A

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

N/A

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RNV Announcements

Latest Announcements

Date Announcements

29 April 25

Quarterly Investor Webinar

×

Quarterly Investor Webinar

29 April 25

ReNerve - Q3 FY25 Activities Report & Appendix 4C

×

ReNerve - Q3 FY25 Activities Report & Appendix 4C

17 April 25

Change in substantial holding

×

Change in substantial holding

10 April 25

Expands Global Footprint with Strategic Partnership in India

×

Expands Global Footprint with Strategic Partnership in India

31 March 25

Response to ASX Aware Letter

×

Response to ASX Aware Letter

28 March 25

Clinical Outcome Demonstrates Material Benefits for Patients

×

Clinical Outcome Demonstrates Material Benefits for Patients

26 March 25

Notification of cessation of securities - RNV

×

Notification of cessation of securities - RNV

20 March 25

Change of Director's Interest Notice - J Chick

×

Change of Director's Interest Notice - J Chick

14 March 25

Application for quotation of securities - RNV

×

Application for quotation of securities - RNV

14 March 25

Cleansing Notice

×

Cleansing Notice

13 March 25

Proposed issue of securities - RNV

×

Proposed issue of securities - RNV

11 March 25

Marketing Approval in Thailand & Initial Sales in Hong Kong

×

Marketing Approval in Thailand & Initial Sales in Hong Kong

07 March 25

ReNerve Receives Additional $139K R&D Refund

×

ReNerve Receives Additional $139K R&D Refund

28 February 25

1HFY25 Results Announcement

×

1HFY25 Results Announcement

28 February 25

1HFY25 Appendix 4D and Half Year Report

×

1HFY25 Appendix 4D and Half Year Report

27 February 25

ReNerve enters distribution partnership in Mexico

×

ReNerve enters distribution partnership in Mexico

14 February 25

Change of Director's Interest Notice - M Panaccio

×

Change of Director's Interest Notice - M Panaccio

10 February 25

Change of Director's Interest Notice - J Chick

×

Change of Director's Interest Notice - J Chick

06 February 25

Quarterly Investor Presentation

×

Quarterly Investor Presentation

31 January 25

Investor Webinar Update

×

Investor Webinar Update

29 January 25

ReNerve - Q2 FY25 Activities Report & Appendix 4C

×

ReNerve - Q2 FY25 Activities Report & Appendix 4C

09 January 25

Becoming a substantial holder

×

Becoming a substantial holder

18 December 24

Change in substantial holding

×

Change in substantial holding

18 December 24

Change of Director's Interest Notice - S Cooper

×

Change of Director's Interest Notice - S Cooper

17 December 24

Change in substantial holding

×

Change in substantial holding

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RNV Shortsell

Frequently Asked Questions

The current share price of Renerve Limited (RNV:ASX) is AU$0.1.
The 52-week high share price for Renerve Limited (RNV:ASX) is AU$0.22.
The 52-week low share price for Renerve Limited (RNV:ASX)? is AU$0.10.
Renerve Limited (RNV:ASX) does not pay a dividend.
Renerve Limited (RNV:ASX) does not pay a dividend.
Renerve Limited (RNV:ASX) has a franking level of 0.0%.
Renerve Limited (RNV:ASX) is classified in the Healthcare.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.